Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by StockingUp21on Jun 28, 2021 12:05pm
148 Views
Post# 33459865

RE:RE:RE:No deals

RE:RE:RE:No deals

Was expected no insider sales and no delay? Because you said that. Apparently straight from CEO who sell shares and delay right after 


GameChangerBet wrote: I think there's too much focus on the interim. The end result is what matters. Regardless of delays, timelines, these are just the bumps in the process which quite honestly should be expected.

What about:
- Successful completion of Phase l and Phase ll with significnt results.
- $75m in cash
- Zero debt
- Within months of starting Phase lll
- $100m USD deal (and more to come)

Don't just dismiss the entire story because something got delayed by a quaretr or two.


 

RalphRalph wrote: If you're implying that there is no interest from Big Pharma, do you believe that Nuance erred in its diligence?  Hard to believe that Mark Lotter would be the only BP exec to see value in the company.

If you're implying that a deal is not likely to finalize anytime soon, I agree with you.




Doccole wrote: If there was deals on the table the ceo wouldn't be selling shares like he did a few weeks ago.

remeber the dates of the amalgamation - when the hold comes up.  I am sure there will be a pump followed by insider dump.  This is going based on Hx here.  I am guessing the beginning of the phase 3 will be similar.

this is opportunity to buy more, but it's risky.  Money maybe stuck here for years.  

 




<< Previous
Bullboard Posts
Next >>